GLP1R and obesity due to melanocortin 4 receptor deficiency: In this systematic review and meta-analysis of 56 RCTs and 79,720 patients with T2DM or obesity, GLP-1 RAs therapy was not associated with an overall higher risk of incident AF, AFL, VAs, and SCD.